Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice

Clinical Cancer Research

Volumn 8, Issue 5, 2002, Pages 1253-1264

  Karashima, Takashi ^a   Sweeney, Paul ^a   Slaton, Joel W ^a   Kim, Sun J ^a   Kedar, Daniel ^a   Izawa, Jonathan I ^a   Fan, Zhen ^b   Pettaway, Curtis ^b   Hicklin, Daniel J ^c   Shuin, Taro ^d   Dinney, Colin P N ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; INTERLEUKIN 8; MESSENGER RNA; PACLITAXEL; PROTEIN P27;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANDROGENS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BLOOD VESSELS; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; HUMANS; INTERLEUKIN-8; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; TYROSINE; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036096775     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Cancer statistics, 2000
2. Management of cancer of the prostate
3. Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer
4. Hormonal and chemotherapeutic systemic therapy for metastatic prostate cancer
5. Regulation of prostatic growth and function by peptide growth factors
6. Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth
7. Growth factors in steroid-responsive prostatic tumor cells
8. Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate
9. Growth of the androgen-dependent tumor of the prostate: Role of androgens and of locally expressed growth modulatory factors
10. Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop
11. The role of growth factors in the human prostate
12. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
13. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
14. Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice
15. Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer
16. Advances in angiogenesis research: Relevance to urological oncology
17. Re: Advances in angiogenesis research: Relevance to urological oncology
18. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique
19. Molecular determinants of angiogenesis in cancer metastasis
20. Tumor angiogenesis
21. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors
22. Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody
23. Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells
24. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells
25. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies
26. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies
27. Mechanism of anti-tumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes
28. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies
29. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
30. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
31. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
32. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma
33. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
34. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma
35. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines
36. Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor-related polypeptides
37. 1arrest in prostatic cancer cell line DU145
38. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor α
39. Autonomous growth of androgen-independent human prostatic carcinoma cells: Role of transforming growth factor α
40. kip1Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells
41. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer
42. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer
43. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice
44. Rapid colorimetic assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
45. In situ mRNA hybridization technique for analysis of metastasis-related genes in human colon carcinoma cells
46. A rapid colorimetric in situ messenger RNA hybridization technique for analysis of epidermal growth factor receptor in paraffin-embedded surgical specimens of human colon carcinomas
47. Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium
48. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma
49. Cip1in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors
50. Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides
51. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor α in the progression of prostatic neoplasms
52. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells
53. Activation of mitogen-activated protein kinase associated with prostate cancer progression
54. Expression of transforming growth factor-α, epidermal growth factor and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia
55. Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-α (TGF-α) and epidermal growth factor (EGF)/TGF-α receptor
56. Expression of mRNA for epidermal growth factor, transforming growth factor-α and their receptor in human prostate tissue and cell lines
57. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
58. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis
59. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
60. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer
61. Highly metastatic human prostate cancer growing within the prostate of athymic nude mice overexpresses vascular endothelial growth factor
62. Taxol-dependent transcriptional activation of I1-8 expression in a subset of human ovarian cancer
63. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: Analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype
64. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer
65. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells
66. Mechanism of action of taxol
67. Taxol: A novel investigational antimicrotubule agent
68. Epidermal growth factor receptor blockade with c225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
69. Perspectives of combined radioimmuno-therapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer
70. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells
71. Epidermal growth factor receptor is increased in multidrug-resistant Chinese hamster and mouse tumor cells
72. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases
73. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy